Maryland Insurance Administration

The meeting focused on proposed regulations concerning the Mental Health Parity and Addiction Equity Act, particularly regarding amendments to section 15-144 of the insurance article. Discussions covered the evolution of federal and state parity laws, the implementation of comparative analysis requirements for non-quantitative treatment limitations, and new data collection standards for health insurance carriers. Stakeholders offered testimony on the necessity of pediatric-specific data for network adequacy, the importance of defining meaningful mental health benefits, and ensuring robust oversight of third-party administrators to prevent bias in access to care.

The workgroup meeting focused on the administrative burdens faced by Federally Qualified Health Centers (FQHCs) due to insurance claim denials, prior authorization requirements, and complex administrative processes. Key discussion points included the impact of these issues on financial stability, patient access, and staff burnout. Participants discussed the complaints process managed by the state administration, the effectiveness of recent prior authorization legislation, and the necessity for improved collaboration between providers and carriers. Additionally, the Maryland State Medical Society provided an introduction for their presentation.

The hearing focused on the submission and processing of clean claims. The Administration sought stakeholder input regarding potential revisions to existing regulations to align with current technological standards. Discussion topics included implementing guardrails for the use of artificial intelligence in claims processing, addressing concerns regarding downcoding, clarifying the clinical criteria supporting emergency department codes, and establishing defined timelines to prevent claims from remaining in an indefinite pending status.

The meeting focused on the definition of specialty drugs and the implications of current coverage requirements. Key discussion topics included concerns regarding pharmacy steering practices, the restricted use of designated pharmacies, and the impact of specialty drug classifications on healthcare costs, patient access, and quality of care. Participants also discussed the necessity of medical management and patient support services for complex or specialty drug therapies.

The hearing focused on reviewing rate increase requests from multiple insurance carriers regarding individual long-term care insurance policies. Key discussions involved the justification for these rate increases, which carriers attributed to industry-wide challenges such as rising morbidity and longevity, as well as lower-than-anticipated lapse rates and interest rate returns. The Administration reviewed the proposed increases for Continental Casualty Company and initiated discussions for Massachusetts Mutual Life Insurance Company, while also addressing policyholder concerns and available options, including reduced benefit plans and contingent non-forfeiture options.